CareDx Inc.
(NASDAQ:CDNA) on Thursday said Medicare has finalized the Local Coverage Determination (LCD) process for molecular testing used to monitor solid organ transplant rejection, affirming coverage across the company's kidney, heart, and lung transplant surveillance offerings.
Following the announcement, the stock jumped nearly 29%.
The precision medicine diagnostics company said the final policy provides continued Medicare coverage for its transplant surveillance portfolio and maintains coverage for clinically indicated, for-cause testing across all three organ types.
Kidney Testing Coverage Remains In Place Under the finalized policy, Medicare will cover surveillance testing with AlloSure Kidney for up to six tests during the first year following a transplant.
